Biotinylated Human CD20 / MS4A1 Full Length Protein, His,Avitag(TM) (Detergent) (SPR verified) 20 ug

Product Overview

• Article Name: Biotinylated Human CD20 / MS4A1 Full Length Protein, His,Avitag(TM) (Detergent) (SPR verified) 20 ug
• Biozol Catalog Number: ABS-CD0-H82E5-20UG
• Supplier Catalog Number: CD0-H82E5-20ug
• Alternative Catalog Number: ABS-CD0-H82E5-20UG
• Manufacturer: AcroBiosystems
• Host: Human
• Category: Proteine/Peptide
• Species Reactivity: Human
• Conjugation: Biotin

Product Description

Blymphocyte antigen CD20 is also known as Blymphocyte surface antigen B1, Leukocyte surface antigen Leu16, Membranespanning 4domains subfamily A member 1 and MS4A1, is an activatedglycosylated phosphoprotein expressed on the surface of all Bcells beginning at the proB phase (CD45R+, CD117+) and progressively increasing in concentration until maturity. CD20 is expressed on all stages of B cell development except the first and last, it is present from late proB cells through memory cells, but not on either early proB cells or plasma blasts and plasma cells. It is found on Bcell lymphomas, hairy cell leukemia, Bcell chronic lymphocytic leukemia, and melanoma cancer stem cells. The protein has no known natural ligand and its function is to enable optimal Bcell immune response, specifically against Tindependent antigens. It is suspected that it acts as a calcium channel in the cell membrane. CD20 / MS4A1 is the target of the monoclonal antibodies (mAb) rituximab, Ibritumomab tiuxetan, and tositumomab, which are all active agents in the treatment of all B cell lymphomas and leukemias. Defects in CD20 / MS4A1 are the cause of immunodeficiency common variable type 5 (CVID5), also called antibody deficiency due to CD20 defect. CVID5 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. - Proteine/Peptide

Product Properties

• Molecular Weight: 36.9 kDa
• Tag: C-12*His & C-Avi
• NCBI: 11836
• Buffer: 50 mM HEPES, 150 mM NaCl, DDM, CHS, pH7.5
• Purity: 90%
• Form: Liquid
• Target: CD20

Images

Immobilized Rituximab biosimilar (Cat. No. CD0-M36) at 2 µg/mL (100 µL/well) can bind Biotinylated Human CD20 Full Length, His,Avitag (Cat. No. CD0-H82E5) with a linear range of 1-15.625 ng/mL (QC tested).

Immobilized Ofatumumab at 2 µg/mL (100 µL/well) can bind Biotinylated Human CD20 Full Length, His,Avitag (Cat. No. CD0-H82E5) with a linear range of 4-63 ng/mL (in presence of DDM and CHS) (QC tested).

Biotinylated Human CD20 Full Length, His,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.

CD0-H82E5-20ug